ライフサイエンスコーパス: brand name

1 d name, or (3) green standardized packs with brand name.

2 data were collected on specific chemicals or brand names.

3 porting on medications with both generic and brand names, 186 (67%; 95% CI, 61%-73%) referred to the

4 ts of 8.0% (difference of proportions versus brand-name, 7.5% [95% confidence interval, -0.9% to 15.9

5 adalimumab biosimilars is similar to that of brand-name adalimumab (Humira, hereinafter originator) i

6 ecutive years following adequate trials of 2 brand-name AEDs.

7 National brand name and generic multivitamin formulations for age

8 viation (total of 79 errors, 11.4%, for both brand name and generic name orders), incorrect dosage ca

9 ured by the occurrence rate of international brand names and trading volumes, is characterized by int

10 isource drug (that is, a drug available in a brand-name and > or =1 generic formulation) or a generic

11 ing drugs with 25 formulations, including 16 brand-name and 9 generic formulations, were included.

12 s that covered brand-name drugs only or both brand-name and authorized generic drugs; approximately 3

13 plan, manufacturer, and Medicare spending on brand-name and authorized generic products.

14 Beneficiary-weighted formulary coverage of brand-name and authorized generic products; beneficiary

15 No measures changed in the brand-name and generic coverage groups.

16 imated by projecting the regression model of brand-name and generic drug competition to observed biol

17 50 (5.0%) met the inclusion criteria for the brand-name and generic drug data set and 28 (2.8%) met t

18 ebo effect), observational studies comparing brand-name and generic drugs are susceptible to bias fav

19 Two separate data sets were created: brand-name and generic drugs as well as biologics and bi

20 me countries, prices may be reduced for both brand-name and generic drugs, but the prevalence of unau

21 the same Medicare reimbursement framework as brand-name and generic drugs, Medicare spending on these

22 ologics and biosimilars differently than for brand-name and generic drugs, which has generated greate

23 y are often concerned that switching between brand-name and generic formulations of antiepilepsy drug

24 3) What is the evidence that brand-name and generic medications have similar clinical

25 0 billion was spent on medications with both brand-name and generic options.

26 g fill patterns for therapies with available brand-name and generic options.

27 Monthly prescriptions of brand-name and generic-equivalent beta-blockers, statins

28 tance, preserving the department's academic "brand name," and ensuring consistent standards and opera

29 emonstrate that the administration of N-803 (brand name Anktiva) and broadly neutralizing antibodies

30 When patented, brand-name antibiotics lose market exclusivity, generics

31 attributable to the reduction in the use of brand-name antidepressants.

32 Bevacizumab, sold under the brand name Avastin, is a humanized mAb that binds VEGF a

33 ught consumer packaged goods (CPGs), whether brands (name brands compared with private labels) matter

34 Brand names can be used to hold plastic companies accoun

35 h only 2.4% of medication fills were for the brand-name choice, they made up 21.2% of total spending.

36 rice increases following the introduction of brand-name competition, suggesting that it may not be ef

37 or one of two porous glasses sold under the brand names CoralPor and Electro-porous KT.

38 and frequently refer to medications by their brand names despite newspaper editors' contention that t

39 itical insights on the developer, commercial brand name, detection methods, technical operational det

40 ach for the total synthesis of calcipotriol (brand name: Dovonex), a proven vitamin D analog used for

41 significant savings on generic medications, brand-name drug discounts were small and overall costs r

42 Once the patent of a brand-name drug expires, generic drugs are commercialize

43 Price change as a percentage of the brand-name drug or biologic price in the quarter before

44 acy benefit managers to pharmacies for every brand-name drug prescription dispensed to all fully insu

45 iotensin-receptor blockers (ARBs) who filled brand-name drug prescriptions and percentage of patients

46 2% decrease (price decline was measured from brand-name drug price before the first generic competito

47 at in all other countries, largely driven by brand-name drug prices that have been increasing in rece

48 questionable merit in place and sustain high brand-name drug prices.

49 Brand-name drug use in Medicare was 2 to 3 times that in

50 ulation would have been $1.4 billion less if brand-name drug use matched that of the VA.

51 the 95th-percentile HRR in the VA had lower brand-name drug use than the 5th-percentile HRR in Medic

52 atus-adjusted hospital referral region (HRR) brand-name drug use was compared, and changes in spendin

53 scribe the factors underlying differences in brand-name drug use.

54 ed a generic drug, and 6380 (7%) initiated a brand-name drug.

55 to assess the time from patent expiration of brand name drugs to marketing of generic drug forms.

56 generic formulations faced restrictions than brand-name drugs (40.5% of generic [67 931 of 167 587] v

57 Off-patent brand-name drugs (cost: >$10 000) were covered by a mean

58 linical efficacy of switching from entecavir-brand-name drugs (ETV-Brand) to entecavir generic drugs

59 Four patented brand-name drugs (sofosbuvir and velpatasvir fixed-dose

60 Of the 19 brand-name drugs analyzed, the retail prices of 7 drugs

61 ditional review pathways for newly available brand-name drugs and biosimilar medicines to treat serio

62 e with generic coverage reduced their use of brand-name drugs and did not switch from brand-name to g

63 PARTICIPANTS: This cohort study analyzed all brand-name drugs and their approved generic versions as

64 creased to eventually include 120 additional brand-name drugs and their generic alternatives when ava

65 Brand-name drugs are sold at high prices in the US durin

66 Clinicians should know that few brand-name drugs are widely covered and check coverage b

67 hanges in spending were calculated if use of brand-name drugs in 1 system mirrored the other.

68 beneficiaries with coinsurance for preferred brand-name drugs increased from 21.9% to 84.0%.

69 Prices of surveyed brand-name drugs increased rapidly between 2009 and 2015

70 s concern among patients and physicians that brand-name drugs may be clinically superior to generic d

71 egulated annual increases in list prices for brand-name drugs may have important consequences for pat

72 of beneficiaries were in plans that covered brand-name drugs only or both brand-name and authorized

73 beneficiaries with coinsurance for preferred brand-name drugs ranged from 0.8% to 2.5% from 2019 to 2

74 ases treated, or unusual price increases, 19 brand-name drugs surveyed in all 4 years were selected f

75 iciaries with diabetes use 2 to 3 times more brand-name drugs than a comparable group within the VA,

76 Part D spending dashboard and any off-patent brand-name drugs that incurred more than $10 000 in Medi

77 as evidence does not support the notion that brand-name drugs used in cardiovascular disease are supe

78 ams and the coverage of expensive off-patent brand-name drugs vs substitutable generic drugs.

79 The relative cash prices for brand-name drugs were 0.97 (CI, 0.96 to 0.97), 1.00 (CI,

80 h prices for a 1-month supply of generic and brand-name drugs were ascertained.

81 lative cash prices for groups of generic and brand-name drugs were estimated for big box, grocery-bas

82 ially older adults with conditions for which brand-name drugs were guideline recommended.

83 Relative differences in cash prices for brand-name drugs were modest across types of retail phar

84 Overall, 73% of generic drugs and 6% of brand-name drugs were widely covered.

85 t's insurance coverage, refuses to prescribe brand-name drugs when generic alternatives are available

86 rovide a last resort for patients in need of brand-name drugs who lack affordable domestic options.

87 TING, AND PARTICIPANTS: A cohort study of 79 brand-name drugs with available pricing data from Januar

88 pharmacists can substitute prescriptions for brand-name drugs with more affordable equivalents, eithe

89 r demographics, insurance type, prior use of brand-name drugs, and calendar month.

90 of generic drugs, which are bioequivalent to brand-name drugs, can help contain prescription drug spe

91 Brand-name drugs, including biologics, have been the pri

92 For 9 high-spending, nonspecialty, brand-name drugs, mean monthly out-of-pocket costs range

93 t least 50% lower than the list price of the brand-name drugs, which should result in savings to pati

94 cteristics can predict patent challenges for brand-name drugs.

95 turer and net prices for insulins and 50 top brand-name drugs.

96 e initial survey requested information on 72 brand-name drugs.

97 c drugs are susceptible to bias favoring the brand-name drugs.

98 The annual ratio of generic to brand-name fenofibrate use in the United States ranged f

99 lothianidin and the pyrethroid deltamethrin (brand name Fludora Fusion) as a new vector control tool.

100 In this cohort study comparing two brand-name fluticasone-salmeterol inhalers prescribed fo

101 Taxol (a brand name for paclitaxel) is widely regarded as among t

102 oequivalence established between generic and brand-name formulations of an immunosuppressive drug in

103 tion was driven by the rapid transition from brand-name formulations to lower-cost generic formulatio

104 1 billion and $0.4 billion, respectively, if brand-name formulations were switched to equivalent gene

105 concurrent rapid decline in the use of their brand-name formulations.

106 Different water brands (different brand names) from the same geographical origin did not s

107 T20 (generic name: Enfuvirtide, brand name: Fuzeon) is the only FDA-approved HIV fusion

108 nts in the generic group versus those in the brand-name group (HR, 0.92 [95% CI, 0.86 to 0.99]).

109 n the generic group and 71% for those in the brand-name group (P<0.001).

110 ored AGs (patients switching from amlodipine brand-name: HR [95% CI] 0.92 [0.88-0.97]).

111 d to determine whether use of generic versus brand-name imatinib differed between patients with a dia

112 ) referred to the study medications by their brand names in at least half of the medication reference

113 tes of similar magnitude with AG compared to brand-name initiation for escitalopram and sertraline (H

114 The comparison between generic and brand-name initiators involved 1,313,161 matched pairs,

115 n list prices for Epclusa, Harvoni, and each brand-name insulin product, respectively.

116 d to extend periods of market exclusivity on brand-name insulin products are filing patents after FDA

117 The modified vaccinia Ankara vaccine (brand names JYNNEOS, Imvamune, and Imvanex) was used in

118 The 4 generic and brand-name levothyroxine preparations studied are differ

119 ce was defined as the screen appearance of a brand name, logo, or identifiable trademark on products

120 verse events was affected for generic versus brand-name losartan users only (difference of proportion

121 Generic competition can be delayed if brand-name manufacturers obtain additional patents on su

122 drugs in the United States is maintained by brand-name manufacturers' competition-free period made p

123 osts and generated the highest percentage of brand name medication claims compared with all other pro

124 ntended to incentivize use of more expensive brand-name medication.

125 Generic medications cost less than brand-name medications and are similarly effective, but

126 medications and are similarly effective, but brand-name medications are still prescribed.

127 In this cross-sectional study, prices of brand-name medications for treatment of NSCLC increased

128 lass changes in US wholesale drug prices for brand-name medications from 2015 to 2020.

129 Low-value services, such as prescribing brand-name medications that have existing generic equiva

130 The study sample was limited to 17 brand-name medications used to treat metastatic NSCLC th

131 out generic medications: 1) How commonly are brand-name medications used when a generic version is av

132 unt of 65% on a generic 3-drug regimen; when brand-name medications were added, discounts were modest

133 ial potential cost savings from substituting brand-name medications with generic medications.

134 the correlation in price among the multiple brand-name medications within each therapeutic class (im

135 ility of free samples and the prescribing of brand-name medications, and the mean cost of acne medica

136 estimated for 9 high-spending, nonspecialty, brand-name medications.

137 s with increased substitution of generic for brand-name medications.

138 ons, if possible, rather than more expensive brand-name medications.

139 .02), and for brand-name vs generic status (brand-name mOR, 8.1 [95% CI, 4.0-16.0] vs generic mOR, 2

140 cted protection from generic competition for brand-name nebulizer solutions (n=13) was 7 years (after

141 all patents and regulatory exclusivities on brand-name nebulizer solutions approved for asthma and C

142 Through the end of 2020, brand-name nebulizers faced generic competition for 62%

143 Relying on brand names of therapy can be misleading.

144 lly produces lower prices, competition among brand-name oncology drugs has not resulted in lower pric

145 (control), (2) white standardized packs with brand name, or (3) green standardized packs with brand n

146 c had been substituted for all corresponding brand-name outpatient drugs in 2000, the median annual s

147 using ritonavir-boosted nirmatrelvir (NVM/r, brand name Paxlovid) may increase risk for adverse cardi

148 c latanoprost, patients who continued taking brand name PGAs were 28% less likely to have improved ad

149 ompared between persons who continued to use brand-name PGAs once generic latanoprost became availabl

150 evaluate trends in prices for newly marketed brand-name prescription drugs in the US from 2008 to 202

151 List prices set by manufacturers for brand-name prescription drugs in the US have been increa

152 There is uncertainty regarding which brand-name prescription drugs will have their prices neg

153 costs for privately insured patients taking brand-name prescription drugs.

154 e generic enoxaparin product relative to the brand name product.

155 Lead was present even in some brand name products from major pharmaceutical companies

156 , and (2) patients initiating generic versus brand-name products (bias-prone direct comparison) and p

157 omparison) and patients initiating AG versus brand-name products (negative control).

158 , drug safety can be adequately ensured, and brand-name products are usually less expensive than in t

159 e identical in composition and appearance to brand-name products but are marketed as generics, as a c

160 cardiovascular endpoint with generics versus brand-name products for amlodipine and amlodipine-benaze

161 Food and Drug Administration (FDA)-approved brand-name products in the same class are indicated for

162 rt study design: (1) patients switching from brand-name products to AGs versus generics, and patients

163 Brand-name products with generic versions that were intr

164 tory exclusivities that limit competition on brand-name products.

165 rized generic alternatives to their patented brand-name products.

166 with comparable clinical outcomes to use of brand-name products.

167 cs, but also generic formulations of current brand-name products.

168 Accounting for estimated brand-name rebates, generic substitution for these medic

169 atients in these programs taking high-priced brand-name specialty drugs.

170 The number of brand-name statin purchases decreased by 90.9% (95% CI,

171 Adjusted HRR-level brand-name statin use ranged (from the 5th to 95th perce

172 Medicare spent $9.6 billion on brand-name statins and ezetimibe and could have saved $2

173 Brand-name statins were used by 18.2% of statin users, a

174 Compared with those initiating brand-name statins, patients initiating generic statins

175 ancer therapeutic paclitaxel (sold under the brand name Taxol), which is derived from yew trees (Taxu

176 gs would be primarily driven by lower use of brand-name therapies by the minority of clinicians who p

177 of brand-name drugs and did not switch from brand-name to generic drugs.

178 8), indicating no evidence of superiority of brand-name to generic drugs.

179 h statins decreased, further substitution of brand-name to generic statins may yield more savings.

180 gs are commercialized, and substitution from brand-name to generics may occur.

181 th AGs versus generics, where AG use proxied brand-name use, addressing negative perception bias, and

182 Physicians may recommend national brand name vitamins and generic brands in tablet form to

183 All national brand name vitamins, both tablet and gel capsule formula

184 OR, 4.6 [95% CI, 3.2-6.7]; P = .02), and for brand-name vs generic status (brand-name mOR, 8.1 [95% C

185 ent's health insurance and the type of drug (brand-name vs generic).

186 trodes, nanoporous glass frits (often of the brand named Vycor) contain the electrolyte solution that

187 Eravacycline (ERV) (brand name Xerava [Tetraphase]) is a new tetracycline-cl

188 Plazomicin (PLZ), brand name ZEMDRI (Cipla Therapeutics), is a novel amino